Emtricitabine Completed Phase 1 Trials for Hepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00545558Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV
NCT01108926PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers
NCT02499874SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women
NCT01562886The Rilpivirine Cerebrospinal-fluid (CSF) Study
NCT03836729Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine
NCT00667433Raltegravir as Early Therapy in African-Americans Living With HIV Study
NCT01040091Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status
NCT00660972Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)
NCT00002335The Safety and Effectiveness of 524W91